How Does Zepbound (Tirzepatide) Work for Weight Loss?

Disclaimer: The content made available on The FORM Website represents the views and opinions of the authors and not those of other entities, such as the manufacturers of products mentioned therein.

Zepbound™ is an injectable medication that is a combination GIP/GLP-1 receptor agonist. It is approved for weight loss in adults with a body mass index (BMI) of 30+ kg/m2 or 27+ kg/m2 with weight related medical problems such as high blood pressure, diabetes and high cholesterol in combination with a low calorie diet and increased physical activity.  It mimics two hormones our body naturally makes: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). GLP-1 acts on the pancreas to stimulate the release of insulin which lowers blood sugar and acts on the brain to decrease appetite and cravings. The addition of a GIP agonist to a GLP-1 agonist has been found to promote additional weight loss. In clinical trials, individuals who took tirzepatide for up to a year and a half, lost an average of 26.6% of their body weight.

Learn more about how FORM prescribes Zepbound  to help patients reach their weight loss goals.

Zepbound™ and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Am I a candidate?

Take our free 3 minute quiz to see if you qualify for FORM.

Lauren Lemieux, MD

Lauren Lemieux, MD

FACP, ABOM diplomate

Dr. Lauren Lemieux completed her Internal Medicine residency and fellowship in Clinical Nutrition at UCLA. She is board certified in Internal Medicine and diplomate of the American Board of Obesity Medicine, and as a Physician Nutrition Specialist. She is also a fellow of the American College of Physicians. Dr. Lemieux is passionate about helping her patients reach their health goals using personalized nutrition, lifestyle and weight management strategies.